Reavis, Zackery W.
Mirjankar, Nikhil
Sarangi, Srikant
Boyle, Stephen H.
Kuhn, Cynthia M.
Matson, Wayne R.
Babyak, Michael A.
Matson, Samantha A.
Siegler, Ilene C.
Kaddurah-Daouk, Rima
Suarez, Edward C.
Williams, Redford B.
Grichnik, Katherine
Stafford-Smith, Mark
Georgiades, Anastasia http://orcid.org/0000-0003-1937-7601
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (P01-HL036587)
Article History
Received: 12 March 2020
Accepted: 9 December 2020
First Online: 18 January 2021
Change Date: 9 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11306-021-01809-z
Compliance with ethical standards
:
: Redford Williams holds a U.S. patent on the use of 5HTTLPR L allele as a marker of increased cardiovascular disease risk. The remaining authors have nothing to disclose.
: The study was approved by the Duke University Medical Center Institutional Review Board.
: The present study was conducted at Duke University Medical Center, and all subjects gave informed consent prior to their participation in the study using a consent form approved by the Duke University Medical Center Institutional Review Board.
: Not applicable (the results presented contain no identifiable information).